Cancer biotech Inhibrx files for USD 75 M IPO
Celgene-partnered biotech Inhibrx aftersecuring USD 40 Million from Viking Global Investors, has filed
for USD 75 million IPO. Built on a
single-domain antibody platform, it has three oncology programs in human
clinical trials, a rare disease program, and two preclinical drugs. Inhibrx,
has also granted Italian-based Chiesi
Farmaceutici, the rights for the development and commercialization of AAT-fusion
protein INBRX-101, outside of North
America. Chiesi will pay USD 10 million upfront and buy a USD 10 million worth
of shares in Inhibrx.
EpimAb Biotherapeutics raises USD 74 M to accelerate bispecific pipeline
Epi...
